Opexa Therapeutics (ACER) vs. Its Peers Financial Comparison
Opexa Therapeutics (NASDAQ: ACER) is one of 286 publicly-traded companies in the “Bio Therapeutic Drugs” industry, but how does it weigh in compared to its rivals? We will compare Opexa Therapeutics to related companies based on the strength of its earnings, institutional ownership, valuation, risk, analyst recommendations, dividends and profitability.
Volatility & Risk
Opexa Therapeutics has a beta of 2.26, suggesting that its stock price is 126% more volatile than the S&P 500. Comparatively, Opexa Therapeutics’ rivals have a beta of 2.94, suggesting that their average stock price is 194% more volatile than the S&P 500.
0.3% of Opexa Therapeutics shares are owned by institutional investors. Comparatively, 50.0% of shares of all “Bio Therapeutic Drugs” companies are owned by institutional investors. 6.9% of Opexa Therapeutics shares are owned by insiders. Comparatively, 17.1% of shares of all “Bio Therapeutic Drugs” companies are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
This table compares Opexa Therapeutics and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Opexa Therapeutics Competitors||-5,273.92%||-220.44%||-39.38%|
This is a summary of current ratings and recommmendations for Opexa Therapeutics and its rivals, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Opexa Therapeutics Competitors||864||3219||11679||232||2.71|
As a group, “Bio Therapeutic Drugs” companies have a potential upside of 46.22%. Given Opexa Therapeutics’ rivals higher possible upside, analysts clearly believe Opexa Therapeutics has less favorable growth aspects than its rivals.
Earnings and Valuation
This table compares Opexa Therapeutics and its rivals gross revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Opexa Therapeutics||$2.90 million||-$7.97 million||-2.05|
|Opexa Therapeutics Competitors||$284.49 million||$33.78 million||75.80|
Opexa Therapeutics’ rivals have higher revenue and earnings than Opexa Therapeutics. Opexa Therapeutics is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.
Opexa Therapeutics rivals beat Opexa Therapeutics on 7 of the 9 factors compared.
Opexa Therapeutics Company Profile
Acer Therapeutics Inc., formerly Opexa Therapeutics, Inc., is a pharmaceutical company. The Company is engaged in acquires, develops and intends to commercialize therapies for patients with serious rare diseases with critical unmet medical need. Its late-stage clinical pipeline includes Edsivo (celiprolol) and ACER-001. The Company is developing Edsivo for the treatment of vascular Ehlers-Danlos Syndrome (vEDS) in the United States. The Company is developing ACER-001, a pharmacologic treatment option for the treatment of Maple Syrup Urine Disease (MSUD). ACER-001 is an immediate-release formulation of sodium phenylbutyrate (NaPB) developed using a microencapsulation process. The Company is also developing ACER-001 for the treatment of Urea Cycle Disorders (UCD).
Receive News & Stock Ratings for Opexa Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opexa Therapeutics and related stocks with our FREE daily email newsletter.